The DOI matches its Crossref record; 182 of the 185 references it cites were found in a registry or an index.
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Open accessAbstract
The ability of cancer cells to suppress apoptosis is critical for carcinogenesis. The BCL2 family proteins comprise the sentinel network that regulates the mitochondrial or intrinsic apoptotic response. Recent advances in our understanding of apoptotic signaling pathways have enabled methods to identify cancers that are “primed” to undergo apoptosis, and have revealed potential biomarkers that may predict which cancers will undergo apoptosis in response to specific therapies. Complementary efforts have focused on developing novel drugs that directly target antiapoptotic BCL2 family proteins. In this review, we summarize the current knowledge of the role of BCL2 family members in cancer development and response to therapy, focusing on targeted therapeutics, recent progress in the development of apoptotic biomarkers, and therapeutic strategies designed to overcome deficiencies in apoptosis. Significance: Apoptosis, long known to be important for response to conventional cytotoxic chemotherapy, has more recently been shown to be essential for the efficacy of targeted therapies. Approaches that increase the likelihood of a cancer to undergo apoptosis following therapy may help improve targeted treatment strategies. Cancer Discov; 5(5); 475–87. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inhibition of MEK/ERK signaling leads to BIM accumulation and increases apoptotic priming in oncogene-driven cancers treated with various targeted therapies, driving cells into an MCL-1 and/or BCL-XL dependent state15,17.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Suppression of MEK/ERK signaling leads to the accumulation of the pro-apoptotic BCL-2 family protein BIM, which is critical for inducing apoptosis in response to an array of targeted therapies14,15.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [15]
In the citing paper
“Many studies have established a central role of the pro-apoptotic BH3 protein BIM in mediating the apoptotic response to targeted therapies (reviewed in [116]).”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citation
Cited by
Sorted by citations
Items 601–625 of 625
Sapuleni, J., Szymanska, M., & Meidan, R. (2022) · Figshare · doi:10.6084/m9.figshare.20327431
Sapuleni, J., Szymanska, M., & Meidan, R. (2022) · Figshare · doi:10.6084/m9.figshare.20327428
Yang, Y., Zhang, Y., Yang, C., Fang, F., Wang, Y., Chang, H., Chen, Z., & Chen, P. (2021) · Figshare · doi:10.6084/m9.figshare.14059345
Zhao, H., Jiang, Y., Lin, F., Zhong, M., Tan, J., Zhou, Y., Liu, L., Li, G., Deng, M., & Xu, B. (2022) · Figshare · doi:10.6084/m9.figshare.19785676
Kumbar, V. M., Peram, M. R., Rooge, S., Kugaji, M. S., Ghagane, S., Mudaraddi, T. Y., & Kulkarni, V. (2025) · Asian Journal of Pharmaceutical Research and Health Care · doi:10.4103/ajprhc.ajprhc_84_25
Optimization and Chemoproteomic Profiling of a Selective, Covalent Bfl-1-Targeting Cellular Tool
Blackwell, J. H., Lucas, S. C. C., Battocchio, G., Börjesson, U., Bostock, M. J., Braybrooke, E. L., Cheung, T., Cottee, M. A., Beaumont, K. C., Gohlke, A., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02581
MitomiRs as Key Players in Metabolic Reprogramming of Blood Cell Development
Koppineedi, V. P., Gutti, M., Padhan, B., Mishra, A., & Gutti, R. K. (2026) · Experientia supplementum · doi:10.1007/978-3-032-06948-1_11
Ohanna, M., Biber, P., Kahil, M., Diazzi, S., Lefevre, L., Larbret, F., Didier, R., Audebert, S., Delmas, V., Larue, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.27.708453
Mitochondrial dynamics: A promising tool for personalized TNBC management
Mishra, H., Yadav, A. K., Kushwaha, V. B., & Singh, M. P. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102157 · Cited by 2
Deep learning localizes focal biology implicated in therapeutic resistance within routine histologyPreprint
Goncalves, T., Pulido-Arias, D., Perrino, C. M., Lomphithak, T., Cleveland, M. C., Dalca, A. V., Gerstner, E. R., Hipp, J., Patel, J., Rosen, B. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.05.723013
Alasmari, A., Panneerselvam, C., Muthupandian, S., & Gebru, G. G. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349314
Wu, J., Kang, H., Huang, Y., Ruan, L., Nan, F., & Sabihi, S.-S. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04544-w
Miao, Z., Hu, M., Li, K., Liu, J., Lin, W., Xiong, W., Zhang, H., & Zhang, Y. (2026) · Cancer Bioscience · doi:10.1016/j.cbs.2026.100011
Ji, J., Wang, X., Liu, L., Zhang, J., Wan, J., Li, G., Xie, G., Qi, J., Xuan, L., Yao, Y., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aea7960
Qiu, J., Liu, H., Ma, X., Du, L., Liu, J., Zhou, Y., Zhao, Y., Zhu, Y., Wang, H., Luo, Y., et al. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168499
BindingDB Entry 50009085: The chemical biology of apoptosis: Revisited after 17 years.
BindingDB (2021) · UC San Diego · doi:10.7270/q2r78jmk
BindingDB (2022) · UC San Diego · doi:10.7270/q28s4tmj
BindingDB (2020) · UC San Diego · doi:10.7270/q25t3p4n
Metadata
- Authors
- Hata, A. N., Engelman, J. A., & Faber, A. C.
- Affiliations
- Harvard University (US)
- Virginia Commonwealth University (US)
- Corresponding author
- Engelman, Jeffrey A.
- Faber, Anthony C.
- Venue
- Cancer Discovery
- Published
- 2015-05-01
- Volume
- 5
- Issue
- 5
- Pages
- 475-487
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4727530
- OpenAlex
- W2067275727
- Cited by
- 619
- References
- 185
- Citations by year
- 2026: 19 · 2025: 48 · 2024: 46 · 2023: 42 · 2022: 69 · 2021: 79 · 2020: 83 · 2019: 79 · 2018: 73 · 2017: 45 · 2016: 29 · 2015: 6
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA127003, R01CA140594, R01CA164273, R01CA137008)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- Bcl-2 family proteins, apoptosis, targeted cancer therapy, mitochondrial apoptosis, cancer therapy response, carcinogenesis, apoptosis resistance
- MeSH terms
- Bcl-2-Like Protein 11, Animals, Antineoplastic Agents, Humans, Membrane Proteins, Neoplasms, Proto-Oncogene Proteins, Signal Transduction, Biomarkers, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Apoptosis Regulatory Proteins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
